Monday, 28 May 2018

You are here

FDA Approves Abaloparatide for High Risk Patients

On April 28th the Food and Drug Administration (FDA) approved abaloparatide (trade name Tymlos) for postmenopausal women with osteoporosis at high risk for fracture due to a history of osteoporotic fracture.  High Risk patients are defined as those with a history of prior osteoporotic fractures, multiple risk factors for fracture, or those unable to take other osteoporosis agents.  (Package insert: http://buff.ly/2pouOOP)

Medscape has reviewed this anabolic agent.  It is intended for high risk postmenopausal women with osteoporosis and is given as a daily 80 μg subcutaneous injection (usually admnistered in the periumbilical region). 

FDA approval is based on results the 18 month ACTIVE trial that included > 2000 women, subcutaneous and showed an 86% reduction in vertebral fractures and 43% reduction nonvertebral fractures.

The product label contains a boxed warning noting that the drug caused a dose-dependent increase in the incidence of osteosarcoma in rats. The effect was observed at systemic exposures to abaloparatide ranging from 4 to 28 times the exposure in humans receiving the 80-μg dose. Whether abaloparatide will cause osteosarcoma in humans is unknown.

Abaloparatide is contraindicated in those with osteosarcoma, Paget's disease, unexplained elevations of alkaline phosphatase, open epiphyses, bone metastases or skeletal malignancies, hereditary disorders predisposing to osteosarcoma, or prior external-beam or implant radiation therapy to the skeleton.

As with Forteo (teraparatide), there is a 2 year lifetime limit on use because of these unknown risks. 

Abaloparatide will be available in the United States in June 2017.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Restless Sleep and Inactivity Intertwined in OA

Adults with osteoarthritis (OA) of the knee who frequently experienced restless sleep were less likely to engage in potentially beneficial moderate-to-vigorous physical activity, analysis of data from the Osteoarthritis Initiative found.

FDA Approves Denosumab for Glucocorticoid-Induced Osteoporosis

Amgen announced that the U.S. Food and Drug Administration (FDA) has approved the use of Prolia® (denosumab) for the treatment of glucocorticoid-induced osteoporosis (GIOP) in men and women at high risk of fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy.

Bisphosphonate Drug Holidays May Result in Fractures

A report in Endocrine Practice shows that drug holidays from bisphosphonates results in a 15% risk of fractures.  (Citation source: http://bit.ly/2FHbFwp)

USPSTF Recommendations on Vitamin D, Calcium Supplementation to Prevent Fractures

The U.S. Preventive Services Task Force (USPSTF) concludes current scientific evidence is insufficient regarding the use of vitamin D and calcium, alone or in combination, to prevent fractures in men and premenopausal women. The USPSTF recommends against daily supplementation with 400 IU or less of vitamin D and 1,000 mg or less of calcium to prevent fractures in postmenopausal women. Current scientific evidence is insufficient regarding the use of vitamin D and calcium at doses greater than 400 IU of vitamin D and greater than 1,000 mg of calcium in postmenopausal women.

Obesity Surgery Tames Knee OA Pain

Laparoscopic gastric band (LAGB) surgery was associated with significant decreases in knee pain from osteoarthritis (OA), with the greatest improvements seen among those whose body mass index (BMI) had the greatest decreases and among younger patients, researchers reported.